Lrrk2 pathogenic substitutions in Parkinson's disease
- PMID: 16172858
- DOI: 10.1007/s10048-005-0005-1
Lrrk2 pathogenic substitutions in Parkinson's disease
Abstract
Leucine-rich repeat kinase 2 (LRRK2) mutations have been implicated in autosomal dominant parkinsonism, consistent with typical levodopa-responsive Parkinson's disease. The gene maps to chromosome 12q12 and encodes a large, multifunctional protein. To identify novel LRRK2 mutations, we have sequenced 100 affected probands with family history of parkinsonism. Semiquantitative analysis was also performed in all probands to identify LRRK2 genomic multiplication or deletion. In these kindreds, referred from movement disorder clinics in many parts of Europe, Asia, and North America, parkinsonism segregates as an autosomal dominant trait. All 51 exons of the LRRK2 gene were analyzed and the frequency of all novel sequence variants was assessed within controls. The segregation of mutations with disease has been examined in larger, multiplex families. Our study identified 26 coding variants, including 15 nonsynonymous amino acid substitutions of which three affect the same codon (R1441C, R1441G, and R1441H). Seven of these coding changes seem to be pathogenic, as they segregate with disease and were not identified within controls. No multiplications or deletions were identified.
Similar articles
-
Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.Neurobiol Aging. 2014 Nov;35(11):2656.e17-2656.e23. doi: 10.1016/j.neurobiolaging.2014.05.025. Epub 2014 Jun 2. Neurobiol Aging. 2014. PMID: 24973808 Free PMC article.
-
LRRK2 R1441G in Spanish patients with Parkinson's disease.Neurosci Lett. 2005 Jul 15;382(3):309-11. doi: 10.1016/j.neulet.2005.03.033. Epub 2005 Apr 13. Neurosci Lett. 2005. PMID: 15925109
-
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.Eur J Hum Genet. 2006 Mar;14(3):322-31. doi: 10.1038/sj.ejhg.5201539. Eur J Hum Genet. 2006. PMID: 16333314
-
Clinical features of LRRK2 parkinsonism.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8. doi: 10.1016/S1353-8020(09)70815-6. Parkinsonism Relat Disord. 2009. PMID: 20082991 Review.
-
Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.J Neural Transm Suppl. 2006;(70):221-9. doi: 10.1007/978-3-211-45295-0_34. J Neural Transm Suppl. 2006. PMID: 17017533 Review.
Cited by
-
Structural analysis of the full-length human LRRK2.Cell. 2021 Jun 24;184(13):3519-3527.e10. doi: 10.1016/j.cell.2021.05.004. Epub 2021 Jun 8. Cell. 2021. PMID: 34107286 Free PMC article.
-
A method for WD40 repeat detection and secondary structure prediction.PLoS One. 2013 Jun 11;8(6):e65705. doi: 10.1371/journal.pone.0065705. Print 2013. PLoS One. 2013. PMID: 23776530 Free PMC article.
-
Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease.Genes (Basel). 2022 Oct 25;13(11):1937. doi: 10.3390/genes13111937. Genes (Basel). 2022. PMID: 36360174 Free PMC article. Review.
-
PARK8 LRRK2 parkinsonism.Curr Neurol Neurosci Rep. 2006 Jul;6(4):287-94. doi: 10.1007/s11910-006-0020-0. Curr Neurol Neurosci Rep. 2006. PMID: 16822348 Review.
-
Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease.Arch Neurol. 2010 Aug;67(8):970-5. doi: 10.1001/archneurol.2010.177. Arch Neurol. 2010. PMID: 20697047 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials